<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01872936</url>
  </required_header>
  <id_info>
    <org_study_id>SPC3649-205</org_study_id>
    <nct_id>NCT01872936</nct_id>
  </id_info>
  <brief_title>Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection</brief_title>
  <official_title>Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santaris Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santaris Pharma A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open-label study is to assess the safety, tolerability, antiviral
      activity, genotype resistance associated with virological failure, pharmacokinetics and
      pharmacodynamics of two dose regimens of miravirsen in combination with telaprevir and
      ribavirin in subjects with hepatitis C virus genotype 1 infection who are null responder to
      pegylated-interferon alpha and ribavirin.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects with a Sustained Virological Response at 24 weeks after the end of therapy.</measure>
    <time_frame>42 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with undetectable HCV RNA levels at end of treatment.</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with a Sustained Virological Response at 12 and 48 weeks after the end of therapy.</measure>
    <time_frame>66 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HCV RNA levels from baseline throughout the study.</measure>
    <time_frame>66 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who experience virological failure throughout the study.</measure>
    <time_frame>66 Weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Viral resistance analysis at baseline and throughout the study.</measure>
    <time_frame>66 Weeks</time_frame>
    <description>The miR-122 seed sites in HCV RNA from subjects at baseline and following viral breakthrough or relapse will be subjected to genotypic sequence analysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma pharmacokinetics (AUC, Cmax, tmax) for miravirsen, telaprevir, and ribavirin levels will be determined.</measure>
    <time_frame>31 Weeks</time_frame>
    <description>A single sample will be collected at select study visits for all subjects through Week 31. A subset of subjects will participate in extended PK sampling for up to 5 hours at select study visits and for up to 24 hours after the last dose of miravirsen.</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine pharmacokinetics for miravirsen levels will be determined.</measure>
    <time_frame>Up to 16 Weeks</time_frame>
    <description>Urine pharmacokinetics (AUC, Cmax, tmax) for miravirsen levels will be measured in a subset of subjects for up to 24 hours after the last dose of miravirsen.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Miravirsen every other week dosing</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 6 every other week doses at 5 mg/kg in combination with telaprevir and ribavirin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Miravirsen monthly dosing</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 3 monthly doses at 7 mg/kg in combination with telaprevir and ribavirin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miravirsen</intervention_name>
    <arm_group_label>Miravirsen every other week dosing</arm_group_label>
    <arm_group_label>Miravirsen monthly dosing</arm_group_label>
    <other_name>SPC3649</other_name>
    <other_name>Miravirsen sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaprevir</intervention_name>
    <arm_group_label>Miravirsen every other week dosing</arm_group_label>
    <arm_group_label>Miravirsen monthly dosing</arm_group_label>
    <other_name>Incivek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>Miravirsen every other week dosing</arm_group_label>
    <arm_group_label>Miravirsen monthly dosing</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of chronic hepatitis C genotype 1 infection

          -  BMI 18 and 38 kg/m2

          -  Null responder to pegylated interferon alpha and ribavirin

        Exclusion Criteria:

          -  Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  Significant liver disease in addition to hepatitis C

          -  Decompensated liver disease medical history or current clinical features

          -  Histologic evidence of hepatic cirrhosis

          -  Concurrent clinically significant medical diagnosis (other than CHC)

          -  Concurrent social conditions (e.g. drugs of abuse, alcohol excess, poor living
             accommodation)

          -  Clinically significant illness within 30 days preceding entry into the study

          -  Participated in an investigational drug study within 30 days or 5 half-lives,
             whichever is longer, prior to the start of study medication

          -  History of clinically significant allergic drug reactions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Hodges, MD</last_name>
    <role>Study Director</role>
    <affiliation>Santaris Pharma A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Liver Institute at Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Specialists of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion de Investigacion de Diego</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <last_update_submitted>November 17, 2014</last_update_submitted>
  <last_update_submitted_qc>November 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

